Results from a preclinical study in mice and a collaborative clinical study in patients show that the type 2 immune response -- associated with parasitic infection and thought to play a negative role ...

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral ...

This trial also includes an open-label portion for adults with type 1 diabetes up to 15 years since diagnosis. The open-label portion (n=40) is examining the efficacy, safety, and durability of ...

EDETEK Inc., a leading global provider of specialized software and services for the biopharma, devices, and diagnostics industries, announced today that it will present at the 2024 The Society for ...

MNV-201 is a mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondriaIn ...

INBRAIN Cortical BCI; Image credit: INBRAIN Neuroelectronics This milestone represents a significant advancement in demonstrating the ability of graphene-based BCI technology beyond decoding and ...

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop ...

To provide flexible and innovative solutions for early development challenges commonly faced by biotech and pharmaceutical ...

Vivani Medical receives approval for the first human trial of its GLP-1 obesity implant in Australia. The LIBERATE-1 trial ...

Hudson Therapeutics, a leading innovator in therapeutic solutions and a US subsidiary of Shaperon, announced Shaperon’s entry ...

Dr. Jeremy Farrar, WHO’s Chief Scientist, emphasized the importance of strengthening country-led R&D and integrating clinical ...